MedTrace Logo

Earlier Diagnosis of Peripheral Neuropathy Using A Simple sCreening Tool (ACT)

NCT07163000 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-09-09

No results posted yet for this study

Summary

This study is looking at people with diabetes (type 1 and type 2 diabetes) to see how well a short questionnaire, called the ACT, can identify nerve damage in the feet and legs (also known as peripheral neuropathy). The investigators will compare the ACT questionnaire to other commonly used tools (the DN4 and Michigan Neuropathy Screening Instrument) and to an eye-test that detects small nerve fibers in the eye (called corneal confocal microscopy, or CCM).

The main goal is to find out if the ACT questionnaire is accurate in detecting nerve damage and painful nerve damage caused by diabetes.

The investigators will also look at whether changes in blood sugar levels, measured with a continuous glucose monitor (Freestyle Libre 3 and iCan), are linked to nerve pain and small nerve fiber damage.

Conditions

Sponsors & Collaborators

  • Procter and Gamble

    collaborator INDUSTRY

  • Hamad Medical Corporation

    collaborator INDUSTRY

  • Weill Cornell Medical College in Qatar

    lead OTHER

Principal Investigators

  • Professor Rayaz A. Malik, PhD · Weill Cornell Medicine - Qatar

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-11
Primary Completion
2026-12-30
Completion
2026-12-30

Countries

  • Qatar

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07163000 on ClinicalTrials.gov